BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 35,627	$ 66,886
Marketable securities, short-term	135,930	176,636
Prepaid expenses and other current assets	6,749	3,093
Total current assets	178,306	246,615
Marketable securities, long-term	59,968	62,553
Restricted cash	232	233
Other assets, long-term	486	724
Total assets	238,992	310,125
Current liabilities
Accounts payable	5,648	1,379
Accrued clinical trial expenses	15,344	4,387
Accrued expenses and other current liabilities	6,615	6,449
Finance lease liability	0	756
Total current liabilities	27,607	12,971
Debt, long-term	29,419	29,897
Other liabilities, long-term	150	284
Total liabilities	57,176	43,152
Commitments and contingencies (Note 11)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2024 and 2023	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2024 and 2023; 60,094,083 and 57,910,461 shares issued and outstanding as of December 31, 2024 and 2023, respectively	6	6
Additional paid-in capital	506,985	489,453
Accumulated deficit	(325,127)	(222,798)
Accumulated other comprehensive income (loss)	(48)	312
Total stockholders’ equity	181,816	266,973
Total liabilities and stockholders’ equity	$ 238,992	$ 310,125